Novo Nordisk Warns Customers About Stolen Insulin

sucujovide.wordpress.com
June 13 /PRNewswire-FirstCall/ -- Novo Nordismk product previously reported as stolen in Northn Carolina has resurfaced recentlyt at a medical centerin Houston. Three lots of 10 ml viald of insulin, marketed under the branfd name Levemir(R) (insulin detemir [rDNA origin] injection), were takenn in the original theft and identifiable by the followinglot XZF0036, XZF0037, XZF0038. A vial or vial s of stolen insulin from lot XZF0037 was discoveresd this week at a medicall center in theHouston area.
Insulin from thesee lots did not circulate through the normal Novo Nordisjk distribution channel and therefore properr storage conditions for the insulin may not have been Patients can locate the lot number on the side of the box of insulinh or the side of the If a patient finds their insulinb is from one of thestolen lots, they shouldf not use the insulin and contact Novo Nordismk Customer Care Center at 1-800-727-6500 for further information and The safety of our patients is of paramouny concern and we are workinfg with our partners, the pharmacy, the FDA and law enforcemenr authorities to investigate the situation and take immediatr steps to maintain the highesty standard of safety and quality for our Levemir(R) is indicated for once- or twice-dailu subcutaneous administration for the treatmen of adult and pediatricx patients with type 1 diabetees mellitus or adult patientds with type 2 diabetes mellitus who requirer basal (long-acting) insulin for the control of Lev emir(R) is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.
Hypoglycemia is the most commojn adverse effect of allinsulin therapies, includingy Levemir(R). As with other insulins, the timing of hypoglycemixc events may differ among variousinsulijn preparations. Glucose monitoring is recommended for all patientswith Levemir(R) is not to be used in insulin infusion Any change of insulin dose should be made cautiouslty and only under medical supervision. Concomitant oral antidiabetesa treatment mayrequire adjustment. Inadequate dosing or discontinuation of treatmenty may lead tohyperglycemia and, in patients with type 1 diabetic ketoacidosis.
Levemir(R) should not be dilutedf or mixed with any other insulin Insulin may cause sodium retention and particularly if previously poor metabolic control is improve d by intensifiedinsulin therapy. Dose and timing of administratiomn may need to be adjustesd to reduce the risk of hypoglycemiq in patients being switchedto Levemir(R) from othedr intermediate or long-acting insulin preparations. The dose of Levemir(R) may need to be adjustedx in patients with renal or hepatic impairment.
Other adverse events commonlyt associated with insulin therapy may include injection sitereactions (on average, 3% to 4% of patient in clinical trials) such as lipodystrophy, redness, itching, hives, swelling, and inflammation. Less common, but more seriousa are severe cases ofgeneralized allergy, including anaphylacticd reaction, which may be life threatening. is a registered trademark of NovoNordism A/S. Novo Nordisk is a healthcare company withan 86-yeard history of innovation and achievement in diabetea care. The company has the broadest diabetes produc t portfolio inthe industry, including the most advanced products within the area of insulinm delivery systems.
In addition to diabete care, Novo Nordisk has a leading position within areas such ashemostasi management, growth hormone therapy, and hormonwe therapy for women. Novo Nordisk's business is driven by the TriplsBottom Line: a commitment to social responsibility to employeeds and customers, environmental soundness and economi c success. With headquarters in Denmark, Novo Nordismk employs more than 27,900 employees in 81 and markets its productss in179 countries. Novo Nordisk'sx B shares are liste d on the stock exchanges in Copenhagen and Its ADRs are listed on the New York Stocmk Exchange under thesymbol 'NVO'. For globap information, visit ; for Unitee States information, visit .